Navigation Links
Westaim announces 2008 year-end results
Date:2/18/2009

., was $18.0 million. In addition, Westaim held ABCP with a book value of $4.3 million.

"Westaim's strong cash position is a significant advantage for the Company as we continue our review of strategic alternatives," said Drew Fitch, President & CEO of Westaim. "Westaim's cash resources, together with the return of capital to be received from NUCRYST in Q1 2009, will provide the Company a strong consolidated footing as we examine new investment opportunities to enhance shareholder value."

The Westaim Corporation's common shares are listed on The Toronto Stock Exchange under the trading symbol WED. Westaim holds a 74.7 percent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS).

A more detailed discussion of Westaim's 2008 consolidated year end results can be found in the 2008 audited consolidated financial statements and Management's Discussion and Analysis, which will be available at www.westaim.com and www.sedar.com

This news release contains forward-looking statements. These statements are based on current expectations that are subject to risks and uncertainties, and Westaim can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to statements regarding Westaim's pursuit of strategic alternatives and examination of possible new investment opportunities in an effort to enhance shareholder value. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. Accordingly, readers are advised not to place undue reliance on forward-looking statements, and should not rely on t
'/>"/>

SOURCE Westaim Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. The Westaim Corporation update on status of short-term investments
2. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. Westaim announces 2007 third quarter results
4. Westaim reduces ABCP exposure
5. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
6. Westaim announces 2007 year-end results
7. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
8. Westaim announces 2008 first quarter results
9. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Second Quarter Results
10. Westaim announces 2008 second quarter results
11. Westaim announces sale of iFire Technology Ltd. assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 Western Connecticut ... DNP, RN, NEA-BC, FAAN who was named The ... and Research in September 2014, is transitioning from ... to lead the development of Western Connecticut Health ... created role, Donahue will be responsible for the ...
(Date:4/20/2015)... NJ (PRWEB) April 20, 2015 The normal ... stroke. There’s nothing more we could do.” Especially if the ... , Today, the response should be much different. So it’s ... question: “What more can be done?” , Not every ... “There is something that can be done.” But, according to ...
(Date:4/20/2015)... 2015 America’s Health Insurance Plans ... insurance industry, is seeking greater regulation of medical ... involving surgical tools called power morcellators ( http://www.morcellatorlawsuit2015.com ... Casey (D-PA) dated April 14th, the group asserted ... to “serious gaps in the current approval and ...
(Date:4/20/2015)... Mesa, CA (PRWEB) April 20, 2015 ... on TROY Secure Print Enterprise (TSPE) software, which provides ... Michigan on Wednesday, May 6 at the Anthem Suite ... Street from 7 to 11 AM. , Beginning at ... breakfast. Starting at 8 AM, TROY Healthcare Solutions will ...
(Date:4/20/2015)... Today the members of the new Stand ... Alliance-National Ovarian Cancer Coalition Translational Research Dream Team ... “DNA Repair Therapies for Ovarian Cancer,” building on ... a common weakness in ovarian cancer. Researchers will ... ovarian cancer by developing a web-based approach to ...
Breaking Medicine News(10 mins):Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurance Trade Group’s Call for Greater Regulation of Medical Devices 4Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4
... March 19 The Pennsylvania,Breast Cancer Coalition (PBCC) will ... at the University of Pennsylvania in the Flyers-76ers,Surgery Theatre ... and Spruce,Streets, to publicize this year,s Income Tax Check-Off ... the eight researchers,who have been selected to receive research ...
... Association Developing New Internet Drug Distributor Identification,Program, ... are now only second to marijuana in the ... street drugs, prescription drugs are,just as dangerous when ... the supervision of a health care practitioner. So ...
... ARLINGTON, Va., March 19 Yesterday,bipartisan groups of ... and,17 U.S. Senators sent letters to the Centers ... the impact of a new Medicare,competitive bidding program ... ask CMS to release data on how the ...
... Chemically altered form of natural compound found in heparin ... health officials say they,ve identified the contaminant found in ... of allergic reactions and possibly 19 deaths in the ... called oversulfated condroitin sulfate, but U.S. Food and Drug ...
... To accommodate rapid growth and,further enhance PRA,s ability to ... office to a larger, more centrally located,facility. By more ... new,location includes more offices and conference and meeting spaces, ... clinical operations,staff while allowing for future expansion of the ...
... (Kingston, ON) Determining how the HIV/AIDS epidemic increases ... be done to reduce the chances of this happening ... , Both Canadian and Southern African expertise ... in policy advocacy around this crucial issue. , Funded ...
Cached Medicine News:Health News:The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign 2Health News:NABP Supports White House's Commitment to End Illegal Internet Drug Sales 2Health News:Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress 2Health News:Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:PRA International Announces New Office Opening in Mumbai 2Health News:Food insecurity linked with HIV/AIDS in Africa 2
(Date:4/20/2015)... Increasing unnecessary regulations on drug plans could inflict higher ... medications through a managed drug plan, according to a ... Analysis Senior Fellow Devon Herrick. "The ... helps makes medications affordable," says Herrick. "Blatant protectionism through ... protections, but more often than not they are designed ...
(Date:4/20/2015)... 20, 2015 Stand Up To Cancer (SU2C) and the ... million Dream Team to attack the number one cancer killer ... of the American Association for Cancer Research (AACR), Scientific Partner ... in the United States will be ... will die from it, making lung cancer the leading cause ...
(Date:4/20/2015)... 2015 Eli Lilly and Company (NYSE: ... was statistically superior to placebo in the treatment of ... the proportion of patients achieving an ACR 20 response. ... 20 percent reduction in disease signs and symptoms as ... During the 24-week, Phase 3 study, titled SPIRIT-P1, patients ...
Breaking Medicine Technology:Restrictive Drug Plan Regulations Will Hurt Patients 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... agonist,linked to doxorubicin. The decision to enter the ...
... integrated neurohormonal ... to obesity pharmacotherapy, SAN DIEGO, Oct. 1 Amylin ... for its pipeline obesity,candidates will be presented at the 2008 ... The Obesity Society,s annual,meeting is one of the largest and ...
Cached Medicine Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: